Business Acquisition Business Acquisition [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Prepaid expenses Increase (Decrease) in Prepaid Expense Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional paid-in capital Additional Paid-in Capital [Member] Licensing Agreements Licensing Agreements [Member] Document Fiscal Period Focus Document Fiscal Period Focus Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding DARE-LARC1 DARE-LARC1 [Member] DARE-LARC1 Gain on early termination of lease Gain (Loss) on Termination of Lease Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Additional potential grant funding Additional Potential Funding Related To Grant Award Additional Potential Funding Related To Grant Award Number of common stock warrants exercised (in shares) Number Of Common Stock Warrants Exercised Number Of Common Stock Warrants Exercised Incremental borrowing rate, amount over prime rate Operating Lease, Incremental Borrowing Rate, Prime Rate Operating Lease, Incremental Borrowing Rate, Prime Rate Common stock, $0.0001 par value; 240,000,000 shares authorized; 86,178,996 and 84,825,481 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Amended and Restated Two Thousand Fourteen Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan Milestone payment paid in common stock Milestone Payments, Contingent Amount Milestone payments, contingent amount. Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Decrease in operating lease ROU assets Increase (Decrease) In Operating Lease Right-of-Use Asset Increase (Decrease) In Operating Lease Right-of-Use Asset Statistical Measurement Statistical Measurement [Domain] Depreciation Depreciation Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Increase in number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease) Hammock Pharmaceuticals, Inc Hammock Pharmaceuticals, Inc. [Member] Hammock Pharmaceuticals, Inc. [Member] Pear Tree Pharmaceuticals, Inc. Pear Tree Pharmaceuticals, Inc. [Member] Pear Tree Pharmaceuticals, Inc. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Offering expenses Sale Of Stock, Brokerage Commissions Expense Sale Of Stock, Brokerage Commissions Expense Issuance of common stock from the exercise of warrants Adjustments to Additional Paid in Capital, Warrant Issued Current liabilities Liabilities, Current [Abstract] March 2023 At The Market Sales Agreement March 2023 At The Market Sales Agreement [Member] March 2023 At The Market Sales Agreement Net loss to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Common stock, shares issued (in shares) Common Stock, Shares, Issued Initial payment Grants Receivable Net loss Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Subsequent Event Type Subsequent Event Type [Axis] Proceeds from the exercise of common stock warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Income Statement Location Income Statement Location [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Component [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Subsequent Event Type Subsequent Event Type [Domain] Non-cash lease expenses Operating Lease, Cost MBI MBI [Member] MBI Grant, DARE-PTB1 Grant, DARE-PTB1 [Member] Grant, DARE-PTB1 Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Catalent and MilanaPharm Catalent and MilanaPharm [Member] Catalent and MilanaPharm Leased Properties Lessee, Operating Leases [Text Block] Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Related Party Related Party [Domain] Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Plan Name Plan Name [Axis] Entity Current Reporting Status Entity Current Reporting Status Other non-current assets Other Assets, Noncurrent Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Supplemental disclosure of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Canceled/forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of operating segments Number of Operating Segments Plan Name Plan Name [Domain] Remainder of 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Project [Axis] Project [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Warrant, exercise price, decrease (in usd per share) Warrant, Exercise Price, Decrease Stock options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Award Type Award Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current portion of lease liabilities Operating Lease, Liability, Current Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Licensed Product or Process for Vaginal or Urological Use Licensed Product or Process for Vaginal or Urological Use [Member] Licensed Product or Process for Vaginal or Urological Use Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property, Plant and Equipment, Net Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Cash paid for measurement of operating lease liabilities Operating Lease, Payments Related Party Transaction [Domain] Related Party Transaction [Domain] Issued shares Sale Of Stock, Prospectus Offering Amount Sale Of Stock, Prospectus Offering Amount Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Employee Stock Option Stock options Share-Based Payment Arrangement, Option [Member] Other non-current assets Increase (Decrease) in Other Noncurrent Assets Canceled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Receivables [Abstract] Receivables [Abstract] Square footage of office space Net Rentable Area Legal Entity Legal Entity [Axis] Other income Other Nonoperating Income (Expense) Expiration Date Class Of Warrant Or Rights Warrants Expiration Date Class of warrant or rights warrants expiration date. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Total liabilities Liabilities Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Class of Warrant or Right Class of Warrant or Right [Axis] Total operating expenses Operating Expenses Maximum Maximum [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Percentage of royalty rate Percentage Of Royalty Rate Percentage of royalty rate. Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax 2022 Stock Incentive Plan Two Thousand Twenty Two Stock Incentive Plan [Member] Two Thousand Twenty Two Stock Incentive Plan Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Cash and Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Total payment Research and Development Agreement, Commitment, Amount Research and Development Agreement, Commitment, Amount Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Small Business Entity Small Business Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Cash paid to stockholders' representative Payments to Stockholders' Representative in Business Combination Payments to Stockholders' Representative in Business Combination Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Going Concern Going Concern [Policy Text Block] Going Concern Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company April and May 2023 At The Market Sales April and May 2023 At The Market Sales [Member] April and May 2023 At The Market Sales Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Accrued expenses Increase (Decrease) in Accrued Liabilities Grant, ADARE-204 and ADARE-214 Grant, ADARE-204 and ADARE-214 [Member] Grant, ADARE-204 and ADARE-214 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Commission percent Percentage Of Aggregate Commission Percentage of aggregate commission. Common stock issued to microchips capital stock holders (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current Warrant exercises, gross Proceeds from Warrant Exercises Title of 12(b) Security Title of 12(b) Security Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date CRADA CRADA [Member] CRADA Subsequent Event [Line Items] Subsequent Event [Line Items] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Total operating lease liabilities Operating Lease, Liability Total assets Assets Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location Income Statement Location [Axis] Antidilutive Securities Antidilutive Securities [Axis] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Accrued expenses Accrued Liabilities, Current Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities October 2021 At The Market Sales Agreement October 2021 At The Market Sales Agreement [Member] October 2021 At The Market Sales Agreement Accounting Policies [Abstract] Accounting Policies [Abstract] Weighted average number of shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Shares of common stock for net proceeds Sale of Stock, Consideration Received on Transaction Sales based milestones amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Accounts payable Accounts Payable, Current Other cost Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Other receivables Increase (Decrease) in Other Receivables Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders' equity. Warrants Warrant [Member] Increase (decrease) operating lease liability Increase (Decrease) in Operating Lease Liability Entity Filer Category Entity Filer Category Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Equity Award Award Type [Domain] Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] Stockholders Equity [Table] Stockholders Equity [Table] Stockholders' equity. Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 7) Commitments and Contingencies Entity Registrant Name Entity Registrant Name Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price License fee revenue License [Member] Class of Warrant or Right Class of Warrant or Right [Domain] DARE-LBT DARE-LBT [Member] DARE-LBT Subsequent Events Subsequent Events [Text Block] Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued Letter of credit related to lease of real property Letters of Credit Outstanding, Amount General and administrative General and Administrative Expense [Member] License and collaboration revenue Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Entity Address, City or Town Entity Address, City or Town Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Leases [Abstract] Operating expenses Operating Expenses [Abstract] Cover [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Annual percentage increase in outstanding number of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum MilanaPharm MilanaPharm [Member] MilanaPharm [Member] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Unamortized stock-based compensation expense Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent Upfront license fee paid Upfront License Fee, Amount Paid Upfront License Fee, Amount Paid Asset acquisition, contingent consideration Asset Acquisition, Contingent Consideration Asset Acquisition, Contingent Consideration Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Total liabilities and stockholders' equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Related Party Related Party [Axis] Warrants Expiring on April 4, 2026 Warrants Expiring On April Four Two Thousand Twenty Six [Member] Warrants expiring on april four two thousand twenty six. Deferred license revenue Contract with Customer, Liability, Noncurrent Research and development Research and Development Expense Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Merger Agreement Merger Agreement [Member] Merger Agreement Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Less: accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Loss per common share - diluted (in usd per share) Earnings Per Share, Diluted Sale of Stock Sale of Stock [Domain] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones [Member] Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones Accounts payable Increase (Decrease) in Accounts Payable Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Subsequent Events [Abstract] Subsequent Events [Abstract] Hennepin License Agreement Hennepin License Agreement [Member] Hennepin License Agreement Total current liabilities Liabilities, Current Grant Awards Grant Award [Text Block] Grant Award [Text Block] NICHD NICHD [Member] NICHD Working capital Working Capital Increase (Deficit) Working Capital Increase (Deficit) Accounting Standards Update 2017-11 Accounting Standards Update 2017-11 [Member] Other current assets Other Assets, Current First commercial sale amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Loss per common share - basic (in usd per share) Earnings Per Share, Basic Remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Prepaid expenses Prepaid Expense, Current Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Product and Service [Axis] Product and Service [Axis] Entity Interactive Data Current Entity Interactive Data Current Sale of stock, number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Weighted average amortization period Weighted Average Amortization Period Weighted Average Amortization Period Equity [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings [Member] Subsequent Event [Table] Subsequent Event [Table] Other receivables Other Receivables, Net, Current Entity Tax Identification Number Entity Tax Identification Number Options to purchase number of outstanding shares of common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Common stock Common Stock [Member] Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Estimated fair value of warrants recorded in equity Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Project [Domain] Project [Domain] Statement [Table] Statement [Table] Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member] Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. Non-cash operating lease cost Non-Cash Lease Expense Non-Cash Lease Expense Renewal term of operating lease Lessee, Operating Lease, Renewal Term Document Quarterly Report Document Quarterly Report Current assets Assets, Current [Abstract] Lease liabilities long-term Operating Lease, Liability, Noncurrent Statistical Measurement Statistical Measurement [Axis] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Milestone payments Research And Development Milestone Payment Research and development milestone payment. Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Equity Components [Axis] Equity Components [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Deferred grant funding Deferred Grant Funding Current Deferred Grant Funding Current Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Strategic Agreements Collaborative Arrangement Disclosure [Text Block] Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Document Fiscal Year Focus Document Fiscal Year Focus Entity Entity [Domain] Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Type of Adoption [Domain] Accounting Standards Update [Domain] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] City Area Code City Area Code Statement [Line Items] Statement [Line Items] General and administrative General and Administrative Expense Assets Assets [Abstract] Other current assets Increase (Decrease) in Other Current Assets Commitments and Contingencies Commitments Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock Sale of Stock [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Right of use asset Operating Lease, Right-of-Use Asset Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Issuance of common stock from the exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Stock-based compensation Share-Based Payment Arrangement, Noncash Expense April 2021 At The Market Sales Agreement April 2021 At The Market Sales Agreement [Member] April 2021 At The Market Sales Agreement Shares underlying outstanding warrants (in shares) Class of Warrant or Right, Outstanding Document Transition Report Document Transition Report Local Phone Number Local Phone Number Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Summary of Stock Option Activity for Amended 2014 Plan and Related Information Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) License fee expense License Fee Expense License Fee Expense Research and development Research and Development Expense [Member] Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Amount awarded for grant Proceeds From Award Of Grant Proceeds From Award Of Grant Operating right-of-use assets obtained in exchange for new operating lease liabilities, net Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Organon Organon [Member] Organon Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Payment of additional consideration Payment of Additional Consideration in Business Combination Payment of Additional Consideration in Business Combination